The partner of choice for pharmaceutical companies
Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.
The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.
How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.
We can help you:
Key benefits:
Key benefits:
Biomedtracker
Get an inside view into the trends powering COVID-era deal making in the life sciences with your free copy of “Biopharma Partnering and Financing Trends, H1 2020”. Informa Pharma Intelligence takes you inside the forces shaping the industry
Topic BIO-Europe
Scrip
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Generics Bulletin
Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.
Scrip
Agreeing that decentralized trials are here to stay, experts discussed in a recent meeting ways in which the pharma research landscape is set to change. With nearly 85% of the industry at different stages of adoption, such trials have seen greater traction in the US, while stricter data privacy laws have hampered progress in Europe, ISCR’s annual conference heard.
Scrip
Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.
Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence
Scrip
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
HBW Insight
More EU countries than you might think allow the terms "prebiotic" and "probiotic" on food supplement labels, suggests a survey from consultancy firm Sandwalk Bioventures. HBW Insight speaks to Sandwalk's managing director, Luis Gosalbez, about a possible move towards liberalization in the region among member states, as well as a way forward for EU regulators lagging behind this localized movement.
Scrip
In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.
Biomedtracker, Scrip
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Scrip
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Topic Coronavirus
Generics Bulletin
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Scrip
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.
HBW Insight
The specialty retailer, entering Target stores in the fall, is aiming for net sales of $7.2bn to $7.3bn in fiscal 2021, compared with $6.15bn in 2020 and $7.4bn in 2019. President Dave Kimbell will be taking the helm in June while CEO Mary Dillon stays on for one year as executive chair of the board.
Scrip
Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.
Scrip
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.
Scrip
13 Apr 2021
Generics Bulletin
13 Apr 2021
Scrip
13 Apr 2021
HBW Insight
13 Apr 2021
Generics Bulletin
13 Apr 2021
HBW Insight
13 Apr 2021
Generics Bulletin
13 Apr 2021
HBW Insight
13 Apr 2021
Scrip
13 Apr 2021
Scrip
13 Apr 2021
HBW Insight
13 Apr 2021
Generics Bulletin
13 Apr 2021
HBW Insight
13 Apr 2021
HBW Insight
13 Apr 2021
Scrip
13 Apr 2021
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: